• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

ACE-inhibitor use associated with decreased conduction system disease

byShayna BejaimalandAnees Daud
June 29, 2016
in Cardiology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this secondary analysis of the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), lisinopril was associated with decreased incidence of conduction system disease when compared with the other antihypertensive medications, amlodipine and chlorthalidone.

2. Clinical factors associated with increased risk of conduction system disease included increased age, male sex, white race, diabetes and left ventricular hypertrophy.

Evidence Rating Level: 2 (Good)

Study Rundown: Different types of cardiac conduction diseases are associated with increased morbidity and mortality. The ALLHAT trial was conducted to study how antihypertensive medications and treatment of dyslipidemia affected cardiovascular mortality and morbidity. This secondary analysis of the ALLHAT trial data aimed to determine if this pharmacological management affected the incidence of cardiac conduction system disease.

When comparing antihypertensive medications, lisinopril was associated with a reduced incidence of developing cardiac conduction disease compared with the other medications studied, chlorthalidone and amlodipine. Clinical factors associated with increased incidence of disease were age, male sex, white race, diabetes and left ventricular hypertrophy. Strengths of the study included long-term follow-up and a large cohort size. Limitations of the study included design, which was a post-hoc secondary analysis that was not designed to study this clinical question.

Click to read the study, published today JAMA Internal Medicine

Relevant Reading: Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

RELATED REPORTS

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

In-Depth [randomized controlled trial]: This study was a secondary analysis of the original ALLHAT study, and conducted to determine the effects of antihypertensives and statin on development of cardiac conduction disease. The original ALLHAT study was a double-blind, randomized trial was conducted in 623 North American centers from 1994 to 2002. Individuals 55 years or older with hypertension and one other cardiac risk factor were included. Those with history of hospitalization for heart failure, severe diastolic or systolic dysfunction were excluded. Patients were randomized to chlorthalidone, amlodipine or lisinopril. All patients underwent baseline ECGs and in this analysis the study population was limited to those without evidence of conduction system disease on their baseline ECG. Follow-up ECGs done every 2 years monitored for incident conduction disease (first-degree atrioventricular block, left anterior fascicular block, incomplete left bundle branch block (LBBB), LBBB, incomplete right bundle branch block (RBBB), RBBB, or intraventricular conduction delay.

Mean follow-up of the 21 004 participants was 5.0 years. Of these, 1114 participants developed conduction disease (570 with RBBB, 389 with LBBB, 155 with intraventricular conduction delay). Overall incidence was 13.0 (95%CI 12.2-13.7) per 1000 person-years for conduction disease. Compared to chlorthalidone, lisinopril was associated with a significant decrease in conduction system disease (HR 0.81; 95%CI 0.69-0.95; p = 0.01). Treatment with amlodipine, or pravastatin was not associated with a significant difference in conduction disease incidence. Clinical factors that were independently associated with increased risk for conduction system disease were increased age, male sex, white race, diabetes and left ventricular hypertrophy.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood pressurecardiovascular riskElectrocardiogram (EKG)
Previous Post

Rehabilitation beneficial for patients with respiratory failure

Next Post

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Cardiology

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

April 20, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

April 7, 2022
Added sugar intake associated with mortality from cardiovascular disease
Cardiology

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

March 16, 2022
Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

March 8, 2022
Next Post
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Earlier puberty associated with increased risk of depression in girls

Escitalopram not linked to improved outcomes in heart failure patients with depression

PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma

PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.